Evidence map›Paper›PMID 41997114›Full record

ArticleCell chemical biology2026

Degrading TBK1 to disarm VHL-deficient renal cancer.

Hyunwoo Kwon, Alan E Bers, David A Barbie

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Hyunwoo KwonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Alan E BersDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
David A BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Parker Institute for Immunotherapy at the Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: david_barbie@dfci.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) with von Hippel-Lindau (VHL) loss exhibits TBK1 dependency, and targeted therapeutic strategies outside of HIF-2α inhibition have remained limited. In this issue of Cell Chemical Biology, Liao et al.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsProtein Serine-Threonine KinasesVon Hippel-Lindau Tumor Suppressor ProteinHumansProteolysis Targeting ChimeraProtein Serine-Threonine KinasesProteolysis Targeting ChimeraTBK1 protein, humanVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID41997114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.